EZH2 and diabetes mellitus: The rare opportunity to examine fresh tissue resected from a donor and the availability of Tazemetostat, the second EZH2 inhibitor approved by the FDA, has allowed a better characterisation of the refractory nature of chromatin underscoring the regenerative barrier of ductal cells derived from the pancreas in diabetic mellitus.